| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
B by Soy Isoflavone Genistein Contributes to Increased Apoptosis Induced by Chemotherapeutic Agents in Human Cancer Cells
Departments of 1 Pathology and 2 Internal Medicine, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan
Requests for reprints: Fazlul H. Sarkar, Department of Pathology, Karmanos Cancer Institute, Wayne State University School of Medicine, 715 Hudson Webber Cancer Research Center, 110 East Warren, Detroit, MI 48201. Phone: 313-966-7279; Fax: 313-966-7558; E-mail: fsarkar{at}med.wayne.edu.
Cancer chemotherapeutic strategies commonly require multiple agents. However, use of multiple agents contributes to added toxicity resulting in poor treatment outcome. Thus, combination chemotherapy must be optimized to increase tumor response and at the same time lower its toxicity. Chemotherapeutic agents are known to induce nuclear factor 
B (NF-B) activity in tumor cells, resulting in lower cell killing and drug resistance. In contrast, genistein has been shown to inhibit the activity of NF-B and the growth of various cancer cells without causing systemic toxicity. We therefore investigated whether the inactivation of NF-B by genistein before treatment of various cancer cells with chemotherapeutic agents could lead to better tumor cell killing as tested by in vitro studies using gene transfections and also by animal studies. PC-3 (prostate), MDA-MB-231 (breast), H460 (lung), and BxPC-3 (pancreas) cancer cells were pretreated with 15 to 30 µmol/L genistein for 24 hours and then exposed to low doses of chemotherapeutic agents for an additional 48 to 72 hours. We found that 15 to 30 µmol/L genistein combined with 100 to 500 nmol/L cisplatin, 0.5 to 2 nmol/L docetaxel, or 50 ng/mL doxorubicin resulted in significantly greater inhibition of cell growth and induction of apoptosis compared with either agent alone. Moreover, we found that the NF-B activity was significantly increased within 2 hours of cisplatin and docetaxel treatment and that the NF-B inducing activity of these agents was completely abrogated in cells pretreated with genistein. These results were also supported, for the first time, by animal experiments, p65 cDNA transfection and p65 small interfering RNA studies, which clearly showed that a specific target (NF-B) was affected in vivo. Collectively, our results clearly suggest that genistein pretreatment inactivates NF-B and may contribute to increased growth inhibition and apoptosis induced by cisplatin, docetaxel, and doxorubicin in prostate, breast, lung, and pancreatic cancer cells. Theses results warrant carefully designed clinical studies investigating the combination of soy isoflavones and commonly used chemotherapeutic agents for the treatment of human cancers.
This article has been cited by other articles:
|
|
 |
|
  Y. Li, T. G. VandenBoom II, D. Kong, Z. Wang, S. Ali, P. A. Philip, and F. H. Sarkar Up-regulation of miR-200 and let-7 by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells Cancer Res., August 15, 2009; 69(16): 6704 - 6712. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Pan, T. Arumugam, T. Yamamoto, P. A. Levin, V. Ramachandran, B. Ji, G. Lopez-Berestein, P. E. Vivas-Mejia, A. K. Sood, D. J. McConkey, et al. Nuclear Factor-{kappa}B p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells Clin. Cancer Res., December 15, 2008; 14(24): 8143 - 8151. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Wilson, C. Purcell, A. Seaton, O. Oladipo, P. J. Maxwell, J. M. O'Sullivan, R. H. Wilson, P. G. Johnston, and D. J. J. Waugh Chemotherapy-Induced CXC-Chemokine/CXC-Chemokine Receptor Signaling in Metastatic Prostate Cancer Cells Confers Resistance to Oxaliplatin through Potentiation of Nuclear Factor-{kappa}B Transcription and Evasion of Apoptosis J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 746 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Meng, N. Mitsutake, M. Nakashima, D. Starenki, M. Matsuse, S. Takakura, H. Namba, V. Saenko, K. Umezawa, A. Ohtsuru, et al. Dehydroxymethylepoxyquinomicin, a Novel Nuclear Factor-{kappa}B Inhibitor, Enhances Antitumor Activity of Taxanes in Anaplastic Thyroid Cancer Cells Endocrinology, November 1, 2008; 149(11): 5357 - 5365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Li, Z. Wang, D. Kong, R. Li, S. H. Sarkar, and F. H. Sarkar Regulation of Akt/FOXO3a/GSK-3{beta}/AR Signaling Network by Isoflavone in Prostate Cancer Cells J. Biol. Chem., October 10, 2008; 283(41): 27707 - 27716. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Schon, B. G. Wienrich, S. Kneitz, H. Sennefelder, K. Amschler, V. Vohringer, O. Weber, T. Stiewe, K. Ziegelbauer, and M. P. Schon KINK-1, a Novel Small-Molecule Inhibitor of IKK{beta}, and the Susceptibility of Melanoma Cells to Antitumoral Treatment J Natl Cancer Inst, June 18, 2008; 100(12): 862 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Rengifo-Cam, S. Umar, S. Sarkar, and P. Singh Antiapoptotic Effects of Progastrin on Pancreatic Cancer Cells Are Mediated by Sustained Activation of Nuclear Factor-{kappa}B Cancer Res., August 1, 2007; 67(15): 7266 - 7274. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Perry, J. M. Spedick, T. P. McCoy, M. R. Adams, A. A. Franke, and J. M. Cline Dietary Soy Protein Containing Isoflavonoids Does Not Adversely Affect the Reproductive Tract of Male Cynomolgus Macaques (Macaca fascicularis) J. Nutr., June 1, 2007; 137(6): 1390 - 1394. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Su, R. R. Eason, Y. Geng, S. Till, T. M. Badger, and R. C.M. Simmen In utero exposure to maternal diets containing soy protein isolate, but not genistein alone, protects young adult rat offspring from NMU-induced mammary tumorigenesis Carcinogenesis, May 1, 2007; 28(5): 1046 - 1051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Dijsselbloem, S. Goriely, V. Albarani, S. Gerlo, S. Francoz, J.-C. Marine, M. Goldman, G. Haegeman, and W. V. Berghe A Critical Role for p53 in the Control of NF-{kappa}B-Dependent Gene Expression in TLR4-Stimulated Dendritic Cells Exposed to Genistein J. Immunol., April 15, 2007; 178(8): 5048 - 5057. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. F. El-Rayes, S. Ali, I. F. Ali, P. A. Philip, J. Abbruzzese, and F. H. Sarkar Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-{kappa}B Cancer Res., November 1, 2006; 66(21): 10553 - 10559. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Auborn Can Indole-3-Carbinol-Induced Changes in Cervical Intraepithelial Neoplasia Be Extrapolated to Other Food Components? J. Nutr., October 1, 2006; 136(10): 2676S - 2678S. [Full Text] [PDF]
|
|
|
|
|
|
J. Domingo-Domenech, C. Oliva, A. Rovira, J. Codony-Servat, M. Bosch, X. Filella, C. Montagut, M. Tapia, C. Campas, L. Dang, et al. Interleukin 6, a Nuclear Factor-{kappa}B Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-{kappa}B Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity. Clin. Cancer Res., September 15, 2006; 12(18): 5578 - 5586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, O. Kucuk, M. Hussain, J. Abrams, M. L. Cher, and F. H. Sarkar Antitumor and Antimetastatic Activities of Docetaxel Are Enhanced by Genistein through Regulation of Osteoprotegerin/Receptor Activator of Nuclear Factor-{kappa}B (RANK)/RANK Ligand/MMP-9 Signaling in Prostate Cancer. Cancer Res., May 1, 2006; 66(9): 4816 - 4825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Sarkar and Y. Li Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res., April 1, 2006; 66(7): 3347 - 3350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Genistein Sensitizes Cancer Cells to Chemotherapy Cancer Res., December 1, 2005; 65(23): 11228 - 11228. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ali, B. F. El-Rayes, F. H. Sarkar, and P. A. Philip Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy Mol. Cancer Ther., December 1, 2005; 4(12): 1943 - 1951. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
